Trial · NCT05178043
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Objective Response Rate (ORR) (confirmed) as evaluated by an Independent Review Committee (IRC) according to RECIST v1.1 | Approximately 2 years | ORR is defined as the proportion of participants with best overall response of confirmed complete response (CR) or partial response (PR). RECIST: Response Evaluation Criteria in Solid Tumors |
| Secondary | Duration OF Response (DOR) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | Progression Free Survival (PFS) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | Time To Response (TTR) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | Time to Progression (TTP) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | Disease Control Rate (DCR) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | ORR (confirmed) as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | DOR as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | PFS as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | TTR as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | TTP as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | DCR as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | ORR (confirmed) as evaluated by an IRC according to HCC mRECIST | Approximately 2 years | |
| Secondary | DOR as evaluated by an IRC according to HCC mRECIST | Approximately 2 years | |
| Secondary | PFS as evaluated by an IRC according to HCC mRECIST | Approximately 2 years | |
| Secondary | TTR as evaluated by an IRC according to HCC mRECIST | Approximately 2 years | |
| Secondary | TTP as evaluated by an IRC according to HCC mRECIST | Approximately 2 years | |
| Secondary | DCR as evaluated by an IRC according to HCC mRECIST | Approximately 2 years | |
| Secondary | ORR (confirmed) as evaluated by the investigator according to HCC mRECIST | Approximately 2 years | |
| Secondary | DOR as evaluated by the investigator according to HCC mRECIST | Approximately 2 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05178043/registered